SCYX Earnings — SCYNEXIS, Inc. Post-ER Performance | BigEarnings
SCYX — SCYNEXIS, Inc.
XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Price$5.64
Market Cap$448.1M
P/E—
52W Range$4.52 – $10.48
Next Earnings2026-08-12
About SCYNEXIS, Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
